Analysts Set Definium Therapeutics, Inc. (NASDAQ:DFTX) Price Target at $37.92

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have been given an average recommendation of “Buy” by the seventeen research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $46.0769.

A number of research analysts have recently weighed in on DFTX shares. Needham & Company LLC raised their price target on Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday. Canaccord Genuity Group set a $60.00 price target on Definium Therapeutics in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. HC Wainwright raised their price target on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, Stifel Nicolaus set a $30.00 price target on Definium Therapeutics and gave the company a “buy” rating in a research report on Thursday, April 16th.

Definium Therapeutics News Summary

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium’s Phase 3 Emerge trial for DT120 met the primary endpoint and all key secondary endpoints, reinforcing confidence in the company’s lead depression program. Article: Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder
• Positive Sentiment: Robert W. Baird raised its price target on DFTX and maintained an outperform rating, while Needham also lifted its target and kept a buy rating, signaling improving Wall Street sentiment. Article: Analysts Are Bullish on These Healthcare Stocks: Definium Therapeutics (DFTX), Apogee Therapeutics (APGE)
• Neutral Sentiment: The company plans a webcast to discuss the trial data, which may provide more detail on durability, safety, and next steps for the program. Article: Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
• Negative Sentiment: Definium also announced a proposed $500 million public offering, which could pressure the stock if investors focus on dilution and financing needs. Article: Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics Trading Down 1.3%

NASDAQ:DFTX opened at $36.18 on Friday. The stock has a fifty day moving average price of $23.28 and a two-hundred day moving average price of $18.75. The stock has a market capitalization of $3.61 billion, a price-to-earnings ratio of -14.53 and a beta of 2.37. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. Definium Therapeutics has a 1 year low of $6.40 and a 1 year high of $39.16.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.23). As a group, sell-side analysts anticipate that Definium Therapeutics will post -2.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in DFTX. Russell Investments Group Ltd. boosted its stake in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares during the last quarter. BIT Capital GmbH acquired a new stake in shares of Definium Therapeutics during the third quarter valued at $26,000. Fifth Third Bancorp boosted its stake in shares of Definium Therapeutics by 5,593.2% during the third quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after acquiring an additional 3,300 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after acquiring an additional 3,020 shares during the last quarter. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Definium Therapeutics during the third quarter valued at $107,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.